Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone312-819-7200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.47 billion
Profitability
Miscellaneous
Employees10,000
Next Earnings Date11/1/2019 (Estimated)
OptionableOptionable
Hill-Rom (NYSE:HRC) Frequently Asked Questions
What is Hill-Rom's stock symbol?
Hill-Rom trades on the New York Stock Exchange (NYSE) under the ticker symbol "HRC."
How often does Hill-Rom pay dividends? What is the dividend yield for Hill-Rom?
Hill-Rom declared a quarterly dividend on Tuesday, July 16th. Stockholders of record on Friday, September 20th will be given a dividend of $0.21 per share on Monday, September 30th. This represents a $0.84 annualized dividend and a dividend yield of 0.80%. The ex-dividend date is Thursday, September 19th. View Hill-Rom's Dividend History.
How were Hill-Rom's earnings last quarter?
Hill-Rom Holdings, Inc. (NYSE:HRC) announced its earnings results on Friday, August, 2nd. The medical technology company reported $1.23 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.21 by $0.02. The medical technology company earned $726.80 million during the quarter, compared to analyst estimates of $718.08 million. Hill-Rom had a return on equity of 21.26% and a net margin of 7.45%. The business's quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the business posted $1.15 earnings per share. View Hill-Rom's Earnings History.
When is Hill-Rom's next earnings date?
What guidance has Hill-Rom issued on next quarter's earnings?
Hill-Rom updated its fourth quarter earnings guidance on Friday, August, 2nd. The company provided EPS guidance of $1.64-1.66 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.67.
What price target have analysts set for HRC?
6 brokers have issued 1 year target prices for Hill-Rom's stock. Their forecasts range from $98.00 to $125.00. On average, they expect Hill-Rom's share price to reach $114.00 in the next year. This suggests a possible upside of 8.3% from the stock's current price. View Analyst Price Targets for Hill-Rom.
What is the consensus analysts' recommendation for Hill-Rom?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hill-Rom in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hill-Rom.
What are Wall Street analysts saying about Hill-Rom stock?
Here are some recent quotes from research analysts about Hill-Rom stock:
- 1. According to Zacks Investment Research, "Hill-Rom exited the second quarter of fiscal 2019 on a strong note with better-than-expected numbers. The company saw a solid year-over-year increase in domestic revenues, driven by sturdy performance in Patient Support Systems and Front Line Care. We are upbeat to note the company’s strong momentum across its diversified product portfolio which includes Centrella Smart+ bed, Welch AllynConnex Spot Monitor, Monarch Airway Clearance System, Integrated Table Motion for the da Vinci Xi Surgical System. The acquisition of Voalte buoys optimism as it boosts Hill-Rom’s digital and mobile communications platform. Overall, Hill-Rom has outperformed its industry in the past six months. However, foreign exchange and a tough competitive landscape remain headwinds. Also, Hill-Rom’s global revenue growth was sluggish in the quarter." (6/6/2019)
- 2. Needham & Company LLC analysts commented, "HRC announced that it has entered into a definitive agreement to acquire Voalte (private) for $180M up front and up to $15M in commercial-based milestones. HRC believes it can absorb the dilutive impact of the deal in FY19, expects the transaction to close in F3Q19, and estimates the deal to become increasingly accretive beginning in FY20. Voalte offers smartphone and web-based applications that enable caregivers to communicate securely and provides managers data analytics tools, respectively. The Voalte deal seems to make financial (accretive to revenue growth and margins) and strategic (further diversifies HRC away from capital equipment sales and allows for cross-selling opportunities in its care communications business) sense, in our view, and we reiterate our Buy rating." (3/11/2019)
Has Hill-Rom been receiving favorable news coverage?
Media headlines about HRC stock have trended negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Hill-Rom earned a coverage optimism score of -2.9 on InfoTrie's scale. They also gave news articles about the medical technology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Hill-Rom.
Who are some of Hill-Rom's key competitors?
Some companies that are related to Hill-Rom include FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Insulet (PODD), ABIOMED (ABMD), Novocure (NVCR), Haemonetics (HAE), Penumbra (PEN), Integra Lifesciences (IART), Globus Medical (GMED), Cantel Medical (CMD), Tandem Diabetes Care (TNDM), NuVasive (NUVA) and ICU Medical (ICUI).
What other stocks do shareholders of Hill-Rom own?
Who are Hill-Rom's key executives?
Hill-Rom's management team includes the folowing people:
- Mr. John P. Groetelaars, Pres, CEO & Director (Age 52)
- Mr. Carlos Alonso-Marum, Sr. VP & Pres of International (Age 60)
- Mr. Paul Johnson, Sr. VP & Pres of Patient Support Systems (Age 54)
- Mr. Steven J. Strobel, Sr. Advisor (Age 61)
- Ms. Barbara W. Bodem, Sr. VP & CFO (Age 51)
Who are Hill-Rom's major shareholders?
Hill-Rom's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.95%), BlackRock Inc. (9.95%), Vanguard Group Inc. (9.46%), Bank of Montreal Can (2.50%), Invesco Ltd. (1.68%) and Bank of New York Mellon Corp (1.68%). Company insiders that own Hill-Rom stock include Alton Shader, Andreas G Frank, Deborah Rasin, John J Greisch, Mary Garrett and Paul Sherwood Johnson. View Institutional Ownership Trends for Hill-Rom.
Which institutional investors are selling Hill-Rom stock?
HRC stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, First Trust Advisors LP, Marshall Wace LLP, Foresters Investment Management Company Inc., Natixis, Natixis, Rothschild & Co. Asset Management US Inc. and Jennison Associates LLC. Company insiders that have sold Hill-Rom company stock in the last year include Andreas G Frank, Deborah Rasin and Paul Sherwood Johnson. View Insider Buying and Selling for Hill-Rom.
Which institutional investors are buying Hill-Rom stock?
HRC stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, BlackRock Inc., BlackRock Inc., Dana Investment Advisors Inc., AQR Capital Management LLC, Vanguard Group Inc., Charles Schwab Investment Management Inc. and Strs Ohio. View Insider Buying and Selling for Hill-Rom.
How do I buy shares of Hill-Rom?
Shares of HRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Hill-Rom's stock price today?
One share of HRC stock can currently be purchased for approximately $105.24.
How big of a company is Hill-Rom?
Hill-Rom has a market capitalization of $7.03 billion and generates $2.47 billion in revenue each year. The medical technology company earns $252.40 million in net income (profit) each year or $4.75 on an earnings per share basis. Hill-Rom employs 10,000 workers across the globe.View Additional Information About Hill-Rom.
What is Hill-Rom's official website?
How can I contact Hill-Rom?
Hill-Rom's mailing address is 130 East Randolph Street Suite 1000, Chicago IL, 60601. The medical technology company can be reached via phone at 312-819-7200 or via email at [email protected]
MarketBeat Community Rating for Hill-Rom (NYSE HRC)
MarketBeat's community ratings are surveys of what our community members think about Hill-Rom and other stocks. Vote "Outperform" if you believe HRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HRC will underperform the S&P 500 over the long term. You may vote once every thirty days.
